3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Waldenstrom Macroglobulinemia
1
Solid Tumor
1
Leukemia
1
Interventions
tislelizumab
3
Paclitaxel
3
Nivolumab
3
pembrolizumab
2
atezolizumab
2
Docetaxel
2
ulocuplumab
1
tazemetostat
1
tazarotene
1
seviteronel
1
rucaparib
1
romiplostim
1
phosphorylethanolamine
1
pertuzumab
1
neratinib
1
magrolimab
1
fluzoparib
1
fludarabine
1
epacadostat
1
durvalumab
1
camrelizumab
1
Trastuzumab
1
Sunitinib
1
Poly(ADP-ribose) Polymerase Inhibitors
1
LY2510924
1
EC145
1
Cyclophosphamide
1
CH5183284
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Solid Tumor
×
ulocuplumab
×
Clear all
NCT02472977
2018-11-01
CXCessoR4
Bristol-Myers Squibb
Phase 1/2
Terminated
61 enrolled
11 charts